Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

키워드

참고문헌 (88)

1. Lai CL, "Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B", J Hepatol, 66, pp.275~281 (2017)
2. Ko C, "Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels", J Hepatol, 69, pp.1231~1241 (2018)
3. Bhat SA, "HBV cccDNA-A culprit and stumbling block for the hepatitis B virus infection : Its presence in hepatocytes perplexed the possible mission for a functional cure", ACS Omega, 7, pp.24066~24081 (2022)
4. Phillips S, "Novel therapeutic strategies for chronic hepatitis B", Virulence, 13, pp.1111~1132 (2022)
5. Shinkai N, "Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance", J Clin Microbiol, 51, pp.3484~3491 (2013)
6. Oone K, "Clinical usefulness of a newly developed high-sensitive hepatitis B surface antigen(HBsAg)assay for monitoring hepatitis B reactivation", Kanzo, 60, pp.237~247 (2019)
7. Shinkai N, "Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay", Liver Int, 37, pp.1138~1147 (2017)
8. Matsumoto A, "Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody", J Gastroenterol, 52, pp.376~384 (2017)
9. Inoue T, "The role of hepatitis B core-related antigen", Genes(Basel), 10, pp.357~ (2019)
10. Takako Inoue, "Novel biomarkers for the management of chronic hepatitis B", Clinical and Molecular Hepatology, 26(3), pp.261~279 (2020), 대한간학회[DOI]
11. Watanabe T, "Hepatitis B core-related antigen and new therapies for hepatitis B", Microorganisms, 9, pp.2083~ (2021)
12. Carey I, "Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(T)ide analogue therapy", Hepatology, 72, pp.42~57 (2020)
13. Inoue T, "Hepatitis B virus and its sexually transmitted infection-an update", Microb Cell, 3, pp.420~437 (2016)
14. "WHO releases first-ever global guidance for country validation of viral hepatitis B and C elimination"[URL]
15. Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
16. European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
17. WHO Guidelines Approved by the Guidelines Review Committee, "Prevention of mother-to-child transmission of hepatitis B virus : Guidelines on antiviral prophylaxis in pregnancy", World Health Organization, ~ (2020)
18. Shimakawa Y, "Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon(ANRS 12303) : a single-centre, longitudinal observational study", Lancet Glob Health, 10, pp.e521~e529 (2022)
19. Drafting Committee for Hepatitis Management Guidelines, "Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection : 2019 update", Hepatol Res, 50, pp.892~923 (2020)
20. Wong DK, "Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA", Liver Int, 37, pp.995~1001 (2017)
21. Kimura T, "Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load", J Clin Microbiol, 40, pp.439~445 (2002)
22. Glebe D, "The molecular virology of hepatitis B virus", Semin Liver Dis, 33, pp.103~112 (2013)
23. Kimura T, "Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain", J Biol Chem, 280, pp.21713~21719 (2005)
24. Xi J, "Multiple roles of PP2A binding motif in hepatitis B virus core linker and PP2A in regulating core phosphorylation state and viral replication", PLoS Pathog, 17, pp.e1009230~ (2021)
25. Hadziyannis E, "Viral biomarkers in chronic HBeAg negative HBV infection", Genes(Basel), 9, pp.469~ (2018)
26. Rokuhara A, "Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment", J Viral Hepat, 10, pp.324~330 (2003)
27. Maasoumy B, "Hepatitis B core-related antigen(HBcrAg)levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D", Clin Microbiol Infect, 21, pp.606~ (2015)
28. Lutgehetmann M, "Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication", Antivir Ther, 13, pp.57~66 (2008)
29. Seto WK, "Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B", Clin Microbiol Infect, 20, pp.1173~1180 (2014)
30. Suzuki F, "Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients", J Med Virol, 81, pp.27~33 (2009)
31. Seto WK, "Evidence of serologic activity in chronic hepatitis B after surface antigen(HBsAg)seroclearance documented by conventional HBsAg assay", Hepatol Int, 7, pp.98~105 (2012)
32. Chuaypen N, "Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B", Liver Int, 36, pp.827~836 (2016)
33. Ma H, "HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon Alfa-2b", Chin Med J(Engl), 129, pp.2212~2219 (2016)
34. Wong DK, "Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection", J Clin Microbiol, 45, pp.3942~3947 (2007)
35. Wang ML, "Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy", Clin Res Hepatol Gastroenterol, 43, pp.301~309 (2019)
36. Lung-Yi Mak, "The role of different viral biomarkers on the management of chronic hepatitis B", Clinical and Molecular Hepatology, 29(2), pp.263~276 (2023), 대한간학회
37. Matsumoto A, "Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy", Hepatol Res, 37, pp.661~666 (2007)
38. Jung KS, "Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients", J Gastroenterol, 51, pp.830~839 (2016)
39. Shinkai N, "Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection", Hepatol Res, 36, pp.272~276 (2006)
40. Hsu YC, "Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk", Aliment Pharmacol Ther, 49, pp.107~115 (2019)
41. Sonneveld MJ, "Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels", J Hepatol, 76, pp.1042~1050 (2022)
42. Tada T, "HBcrAg predicts hepatocellular carcinoma development : An analysis using time-dependent receiver operating characteristics", J Hepatol, 65, pp.48~56 (2016)
43. Tseng TC, "High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load", Gastroenterology, 157, pp.1518~1529 (2019)
44. Tseng TC, "Hepatitis B core-related antigen stratifies the risk of liver cancer in HBeAg-negative patients with indeterminate phase", Am J Gastroenterol, 117, pp.748~757 (2022)
45. Ando Y, "Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment", Hepatol Res, 48, pp.E240~E251 (2018)
46. Wong GL, "Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy", World J Gastroenterol, 19, pp.6515~6522 (2013)
47. Honda M, "Hepatitis B virus(HBV)core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma", J Infect Dis, 213, pp.1096~1106 (2016)
48. Cheung KS, "Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy", J Viral Hepat, 24, pp.654~661 (2017)
49. Kaneko S, "Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigennegative chronic hepatitis B patients", J Gastroenterol Hepatol, 36, pp.2943~2951 (2021)
50. Kumada T, "Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients : a propensity score analysis", J Hepatol, 58, pp.427~433 (2013)
51. Hosaka T, "Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues", Aliment Pharmacol Ther, 49, pp.457~471 (2019)
52. Suzuki Y, "Hepatitis B virus(HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma", Hepatol Res, 49, pp.51~63 (2019)
53. Chen S, "Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients", Clin Chim Acta, 486, pp.237~244 (2018)
54. Hosaka T, "HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy", Liver Int, 30, pp.1461~1470 (2010)
55. Seto WK, "Association of hepatitis B core-related antigen with hepatitis B virus reactivation in occult viral carriers undergoing high-risk immunosuppressive therapy", Am J Gastroenterol, 111, pp.1788~1795 (2016)
56. Höner Zu Siederdissen C, "What is new on HBsAg and other diagnostic markers in HBV infection?", Best Pract Res Clin Gastroenterol, 31, pp.281~289 (2017)
57. Liu S, "Serum hepatitis B virus RNA : A new potential biomarker for chronic hepatitis B virus infection", Hepatology, 69, pp.1816~1827 (2019)
58. Huang H, "Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals", J Clin Virol, 99-100, pp.71~78 (2018)
59. Liu YY, "Progression and status of antiviral monitoring in patients with chronic hepatitis B : From HBsAg to HBV RNA", World J Hepatol, 10, pp.603~611 (2018)
60. Chen EQ, "Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA", J Viral Hepat, 26, pp.586~595 (2019)
61. Inoue T, "Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation", J Hepatol, 75, pp.302~310 (2021)
62. Yaginuma K, "Hepatitis B virus(HBV)particles are produced in a cell culture system by transient expression of transfected HBV DNA", Proc Natl Acad Sci U S A, 84, pp.2678~2682 (1987)
63. Hagiwara S, "Management of hepatitis B virus(HBV)reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay", Hepatol Res, 52, pp.745~753 (2022)
64. Suzuki T, "Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation", J Gastroenterol, 57, pp.486~494 (2022)
65. Suzuki F, "Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance", Hepatol Res, 51, pp.426~435 (2021)
66. Hosaka T, "Ultrasensitive assay for hepatitis B core-related antigen predicts hepatocellular carcinoma incidences during entecavir", Hepatol Commun, 6, pp.36~49 (2022)
67. Wong DK, "A longitudinal study to detect hepatitis B surface and corerelated antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays", J Clin Virol, 160, pp.105375~ (2023)
68. Hsieh YC, "Serum HBcrAg and hepatocellular carcinoma in a Taiwanese population seronegative for HBsAg and Anti-HCV", Clin Gastroenterol Hepatol (2022)[DOI]
69. Shimakawa Y, "Hepatitis B core-related antigen : An alternative to hepatitis B virus DNA to assess treatment eligibility in Africa", Clin Infect Dis, 70, pp.1442~1452 (2020)
70. Shimakawa Y, "Analytical validation of hepatitis B corerelated antigen(HBcrAg)using dried blood spots(DBS)", J Viral Hepat, 28, pp.837~843 (2021)
71. Shimakawa Y, "Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings", Clin Gastroenterol Hepatol (2022)[DOI]
72. Janssen HLA, "Randomised phase 2 study(JADE)of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection", Gut (2023)[DOI]
73. Yamamoto N, "Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection", J Hepatol, 64, pp.547~555 (2016)
74. Yuen MF, "Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU", ml threshold, 2019, pp.70(Suppl), e51~e52
75. Yuen MF, "Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B : a phase 2 randomized controlled trial", Nat Med, 27, pp.1725~1734 (2021)
76. Han K, "A randomized, double-blind, placebo-controlled, first-timein-human study to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GSK3389404in healthy subjects", Clin Pharmacol Drug Dev, 8, pp.790~801 (2019)
77. Block TM, "Host RNA quality control as a hepatitis B antiviral target", Antiviral Res, 186, pp.104972~ (2021)
78. Mueller H, "A novel orally available small molecule that inhibits hepatitis B virus expression", J Hepatol, 68, pp.412~420 (2018)
79. Hwang N, "Hepatoselective dihydroquinolizinone Bis-acids for HBsAg mRNA degradation", ACS Med Chem Lett, 12, pp.1130~1136 (2021)
80. Liu F, "Host poly(A)polymerases PAPD5 and PAPD7provide two layers of protection that ensure the integrity and stability of hepatitis B virus RNA", J Virol, 95, pp.e0057421~ (2021)
81. Delahaye J, "Combination treatment of a PAPD5", 7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model, 2022, pp.77(Suppl), S880~
82. Jer-Wei Wu, "Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(4), pp.524~534 (2021), 대한간학회[DOI]
83. Wang Y, "Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients", Int J Med Sci, 19, pp.858~866 (2022)
84. Wang L, "Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients", J Clin Microbiol, 57, pp.e01303-18~ (2019)
85. Huang PY, "The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients", J Viral Hepat, 28, pp.1141~1149 (2021)
86. Seto WK, "Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation", Gut, 70, pp.775~783 (2021)
87. Ghany MG, "Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America", Hepatology, 74, pp.2395~2409 (2021)
88. Hoofnagle JH, "A modern therapy for an ancient disease", N Engl J Med, 387, pp.1996~1998 (2022)

관련 논문AI추천